(NASDAQ: ACET) Adicet Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Adicet Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ACET's revenue for 2026 to be $1,654,192,500, with the lowest ACET revenue forecast at $1,654,192,500, and the highest ACET revenue forecast at $1,654,192,500. On average, 1 Wall Street analysts forecast ACET's revenue for 2027 to be $2,621,895,113, with the lowest ACET revenue forecast at $2,621,895,113, and the highest ACET revenue forecast at $2,621,895,113.
In 2030, ACET is forecast to generate $16,826,694,239 in revenue, with the lowest revenue forecast at $16,826,694,239 and the highest revenue forecast at $16,826,694,239.